Featured Research

from universities, journals, and other organizations

Response to preoperative therapy may predict survival in pancreatic cancer patients

Date:
May 28, 2010
Source:
Fox Chase Cancer Center
Summary:
New research finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

Cancer of the pancreas -- a glandular organ that lies behind the stomach and secretes vital enzymes and hormones -- seldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

The research, led by Yun Shin Chun, M.D., a surgical oncologist at Fox Chase, is being presented at the 46th Annual Meeting of the American Society of Clinical Oncology on June 6.

Since the 1980s, Fox Chase has been committed to finding better treatments for this intractable disease. In 1986, the Center conducted the first trial in pancreatic cancer of "multimodal" preoperative therapy (the use of more than one kind of treatment, such as chemotherapy and radiation, to kill tumor cells before surgery), and a phase I trial of gemcitabine in the 1990s established the safe dosage for the chemotherapy drug, now widely used in treating the disease.

In the current study, Chun and colleagues wanted to know whether response to preoperative therapy predicts survival in pancreatic adenocarcinoma--the most common type of pancreatic cancer. "For many cancers--breast, esophagus, stomach, and colorectal liver metastases--it has been shown that survival is much better in people who have a good pathologic response to preoperative therapy--meaning that many tumor cells are killed--than in people who do not have a good pathologic response," says Chun. "But this has not been established in pancreatic cancer; previous studies have shown conflicting results."

In hopes of clearing up the confusion, Chun and colleagues reviewed data on 135 patients who had preoperative therapy and surgery. Fox Chase pathologist Harry Cooper, M.D., examined slides of the patients' tumors and classified their response to preoperative treatment as minor, partial, or major, based on the amount of fibrosis (scarring) in tumor tissue. For patients whose tumors showed major response to preoperative therapy, the median survival was more than five years, compared to seventeen months for those who showed minor response.

Although major response is relatively rare--only 19 percent of patients in the study were so classified--the findings give researchers and clinicians important information to build upon. "Going forward, if we can identify molecular factors in tumors associated with a major pathologic response, then we can make important progress in this disease," says Dr. Chun.

In addition to Chun and Cooper, the paper's authors are James Watson, M.D., F.A.C.S.; and John P. Hoffman, M.D., F.A.C.S.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Response to preoperative therapy may predict survival in pancreatic cancer patients." ScienceDaily. ScienceDaily, 28 May 2010. <www.sciencedaily.com/releases/2010/05/100528211148.htm>.
Fox Chase Cancer Center. (2010, May 28). Response to preoperative therapy may predict survival in pancreatic cancer patients. ScienceDaily. Retrieved August 20, 2014 from www.sciencedaily.com/releases/2010/05/100528211148.htm
Fox Chase Cancer Center. "Response to preoperative therapy may predict survival in pancreatic cancer patients." ScienceDaily. www.sciencedaily.com/releases/2010/05/100528211148.htm (accessed August 20, 2014).

Share This




More Health & Medicine News

Wednesday, August 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com
101-Year-Old Working Man Has All The Advice You Need

101-Year-Old Working Man Has All The Advice You Need

Newsy (Aug. 19, 2014) Herman Goldman has worked at the same lighting store for almost 75 years. Find out his secrets to a happy, productive life. Video provided by Newsy
Powered by NewsLook.com
Researcher Testing on-Field Concussion Scanners

Researcher Testing on-Field Concussion Scanners

AP (Aug. 19, 2014) Four Texas high school football programs are trying out an experimental system designed to diagnose concussions on the field. The technology is in response to growing concern over head trauma in America's most watched sport. (Aug. 19) Video provided by AP
Powered by NewsLook.com
American Ebola Patient Apparently Improving, Outbreak Is Not

American Ebola Patient Apparently Improving, Outbreak Is Not

Newsy (Aug. 19, 2014) Nancy Writebol, an American missionary who contracted Ebola, is apparently getting better, according to her husband. The outbreak, however, is not. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins